LONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
Results to Inform Development Plan and Dose Selection for Phase 3 LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq:...
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company...
LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company...
LONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to...
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage...
Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed ...
Initiated Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator Initiated first Phase 2 study with metered-dose...
Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead ...
...
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a biopharmaceutical company...
LONDON, July 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
LONDON, July 24, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.